Published price vs quote-only
Shed vs Hers: Which One Publishes Its Price? (2026)
Shed quotes after intake vs Hers $149/mo. 2026 comparison of pricing, medication and support, with 12-month totals rather than first-month offers.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.9 and 9.8 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Anyone shortlisting Shed against Hers is choosing between two direct-pay GLP-1 programs that solve the same problem in materially different ways.
A discount off an undisclosed number is not a price. Shed quotes after intake, while Hers states Wegovy pill from $149/mo, injectable from $199/mo on the way in — which makes one of these two comparable in advance and the other not.
Rather than restate two feature lists, this compares the two on cost over time, medication access, price stability and the support each one includes. Undisclosed pricing is treated as a finding, not rounded into an estimate.
The short answer
- Easier to price in advance
- Hers — Wegovy pill from $149/mo, injectable from $199/mo. The other side quotes after intake, so a like-for-like total is not available before you apply.
- FDA-approved medication
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — a finished product the FDA has reviewed, rather than a compounded preparation.
- Fastest route to a first shipment
- Hers — Online intake with clinician review, then home delivery, no insurance required.
- Longest public track record
- Shed — 8,500 patient reviews against 6,200.
Side-by-side comparison
Two programs, side by side, on their own published terms — with the rows that differ doing the work.
| Shed | Hers | |
|---|---|---|
| Advertised price | 10% off the first month, price quoted after intake | Wegovy pill from $149/mo, injectable from $199/mo |
| Rate after promotions | not published before intake | $149/mo |
| Pricing structure | Quoted only after intake | Published rate per medication |
| Medication | Name-brand FDA-approved GLP-1 and compounded GLP-1 | FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen |
| Price transparency | Quote only, after intake | Published upfront |
| How fast you start | 2-minute approval assessment | Online intake with clinician review |
| Membership fee | Not stated | None |
| State coverage | Not published | Not published |
| Support model | Coaching built into the plan | Provider check-ins included |
| Patient reviews | 8,500 | 6,200 |
| eRxDoctor score | 9.9/10 | 9.8/10 |
What you will have spent by month twelve
A first-month price is a customer-acquisition number. The figures underneath convert both offers into what you will have spent by month six and month twelve.
| Shed | Hers | |
|---|---|---|
| First month | Not published | $149 |
| Months 2 onward | Not published | $149/mo |
| 6-month total | Not computable | $894 |
| 12-month total | Not computable | $1,788 |
| Best published plan | No multi-month discount published | No multi-month discount published |
A like-for-like annual total is not available for Shed: Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. Treat any comparison that quotes one as an estimate someone else has made for you.
What you know before you hand over a medical history
Hers publishes Wegovy pill from $149/mo, injectable from $199/mo before intake. That is the baseline condition for comparing two programs at all.
Shed withholds the figure until 2-minute approval assessment is complete — Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. Whatever the reason, it moves the price conversation to after your commitment rather than before it.
The workaround is straightforward: complete Shed's assessment, get the quote, and then price it against Hers's published $149/mo before agreeing to anything.
Inside the Shed program
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month. In this pairing, its distinguishing feature is one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it.
From signup to first shipment: 2-minute approval assessment, then home delivery after clinician review. Billing follows a quoted only after intake structure.
What continues after the first shipment: continuous coaching built into every treatment plan. Formulary: name-brand FDA-approved GLP-1 and compounded GLP-1.
Shed pros
- 10% off your first month for new patients
- Fast 2-minute approval assessment
- Continuous coaching is integrated into treatment, not just a prescription
- Offers both FDA-approved name-brand GLP-1 and compounded options on one platform
Shed cons
- Name-brand options carry significantly higher costs than compounded alternatives
- Standard pricing is not published, you receive a personalized quote after intake
- Coaching-bundled model can cost more than bare-prescription platforms
Read next to Hers, the weak point: you cannot know what you will pay until you have finished the intake.
Hers in detail
Hers offers FDA-approved Wegovy® (brand-name semaglutide) with a personalized care team and ongoing dose check-ins, no compounded medications. What it is really selling here is brand-name Wegovy at a price that usually buys compounded medication elsewhere.
Practically: online intake with clinician review, home delivery, no insurance required, and a pricing model that is published rate per medication.
On the clinical side, personalized care team with ongoing dose check-ins, prescribing FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers pros
- No insurance required
- FDA-approved brand-name Wegovy®, not a compounded product
- Personalized care team with ongoing dose check-ins
Hers cons
- No compounded/generic alternative offered
- Higher starting price than most compounded competitors
Where it gives ground to Shed: there is no compounded tier to fall back on if the brand-name price stops working for you.
Who each program is actually built for
Choose Shed if:
- delivery works the way you want it to: home delivery after clinician review
- you want to start on their timeline: 2-minute approval assessment
- the level of clinical contact suits you: continuous coaching built into every treatment plan
- what it leads on is worth paying for in your case: one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it
Choose Hers if:
- you want the full price in front of you before completing an intake
- you want an FDA-approved finished medication rather than a compounded preparation
- the level of clinical contact suits you: personalized care team with ongoing dose check-ins
- the feature you would actually use: brand-name Wegovy at a price that usually buys compounded medication elsewhere
Honest trade-offs
On price. Only Hers publishes a rate you can plan against (Wegovy pill from $149/mo, injectable from $199/mo). The other quotes after intake, which is a cost of a different kind: you cannot budget the year in advance.
On commitment. Neither publishes a multi-month discount, so both are month-to-month decisions and neither asks you to prepay for a response you have not had yet. Neither publishes financing options, so plan for the full amount each month.
On medication. Shed covers name-brand FDA-approved GLP-1 and compounded GLP-1; Hers covers FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen. Neither locks you out of a molecule the other offers, so this is unlikely to be the deciding factor.
On clinical contact. Continuous coaching built into every treatment plan at Shed; personalized care team with ongoing dose check-ins at Hers. Neither is a substitute for in-person care if you have complicating conditions, and both bill you directly rather than your insurer.
What the evidence actually says
The efficacy data people cite when comparing these platforms is not platform data. It comes from trials of the underlying medication, and it applies to both.
The SELECT trial found semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, without diabetes, per NEJM, SELECT.
NIDDK frames medication as one component of obesity treatment rather than a replacement for the rest of it, per NIH, NIDDK.
Which is to say: the medication decision belongs with a clinician, and the platform decision belongs with a spreadsheet.
Shed vs Hers: common questions
How much does Shed cost?
Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. That is the honest answer, and it is the main practical drawback next to Hers, which publishes Wegovy pill from $149/mo, injectable from $199/mo upfront. If you go through the intake, ask for the month-two and maintenance-dose prices in writing before paying for the first month.
Which is cheaper to start, Shed or Hers?
Only Hers publishes a first-month figure (Wegovy pill from $149/mo, injectable from $199/mo). The other quotes after intake, so a starting-cost comparison is not available in advance.
Is coaching included with Shed or Hers?
Shed includes continuous coaching built into every treatment plan in the monthly price. Hers provides personalized care team with ongoing dose check-ins, without a separate coaching program. If medication alone has failed you before, the bundled version is the one to price properly rather than the one to cut.
How fast can I start with Shed compared with Hers?
Shed advertises 2-minute approval assessment, with home delivery after clinician review. Hers advertises online intake with clinician review, with home delivery, no insurance required. Both are subject to clinician review and to whether your state and health history clear, so treat the advertised timeline as a best case rather than a commitment.
Are Shed and Hers legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Shed operates on quoted only after intake with pricing quote only, after intake, Hers on published rate per medication, published upfront. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
The verdict
Neither of these two publishes enough for a clean cost verdict, which is itself the finding. Shed leads on one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it; Hers leads on brand-name Wegovy at a price that usually buys compounded medication elsewhere.
Before choosing either, get the maintenance-dose price in writing. Without it, any comparison — including this one — is working with half the information.
Whichever you choose, diarise the month the introductory pricing ends and re-run the comparison then. Neither platform will remind you.
Keep comparing
- Shed vs Mochi HealthPublished price vs quote-only
- Shed vs NoviPublished price vs quote-only
- Hers vs WellorithmBrand-name vs compounded
- Hers vs EmbodyBrand-name vs compounded
- Directmeds vs He & She MDPublished price vs quote-only
- Directmeds vs MaximusPublished price vs quote-only
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Shed or Hers, and does not sell treatment. Read our ranking methodology.